The foundation:

Carla Abdelnour, internationally recognized in the field of clinical trials

Carla Abdelnour, a neurologist at Fundació ACE, has been elected representative of the Executive Committee of the Area of Professional Interest on Advances and Methods of Clinical Trials of the International Society for the Advancement of Alzheimer's Research and Treatment (ISTAART), which is part of the Alzheimer's Association.

Abdelnour is deputy director of the Clinical Trials Unit and coordinator of Fundació ACE Social Technology and Robotics Research (FACESTARR). 

Greg Jicha, President of the area of Clinical Trials Advances and Methods, has notified his election to the expert of Fundació ACE. 

Her term will begin at the end of the Annual Conference of the Alzheimer's Association (AAIC 2020), which is scheduled to take place between 26 and 30 July in Amsterdam.

Dr. Abdelnour has expressed her deep appreciation for this new responsibility and said that for her it represents "an opportunity to exchange knowledge in this difficult and exciting task of finding a cure for Alzheimer's disease and other dementias". 

She has added that she is very happy "to know that I will meet people who share this common interest, and that we will make progress in developing innovative aspects in trials such as remote assessments or patient-centred care". 

The deputy director of Fundació ACE's Clinical Trials Unit leads the ACE's dementia with Lewy bodies research and is a member of the steering committee of the European Dementia with Lewy Bodies Consortium (E-DLB). 

She is also coordinator of the Cognition and Behaviour Study Group of the Catalan Society of Neurology. She is currently a pre-doctoral student in the Department of Medicine at the Autonomous University of Barcelona and has published more than twenty articles in indexed journals to date. 

You might also like

Dr. Carla Abdelnour will talk about how robots can contribute to a cure for people with Alzheimer

Dr. Carla Abdelnour will talk next Friday about how robots can contribute to a cure for people with Alzheimer.